THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to ...
Atara is working closely with its partners and the FDA to lift clinical hold and support EBVALLO™ BLA resubmission in the U.S. Atara remains focused on delivering on the future financial value ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback